Interleukin-6 Levels and Painful Neuropathy in Breast Cancer Patients
Author Information
Author(s): Angela Starkweather
Primary Institution: Virginia Commonwealth University
Hypothesis
The study aims to evaluate levels of interleukin-6 and its receptors in women with breast cancer after chemotherapy, comparing those with and without painful symptoms of chemotherapy-induced peripheral neuropathy.
Conclusion
Women with painful chemotherapy-induced peripheral neuropathy had significantly higher levels of interleukin-6 and its soluble receptor compared to those without symptoms.
Supporting Evidence
- CIPN participants had significantly higher levels of IL-6 and soluble IL-6R compared to women without CIPN symptoms.
- Soluble gp130 was significantly lower in the CIPN group compared to the comparison group.
- The density of IL-6R on monocytes was inversely correlated with circulating levels of sIL-6R.
Takeaway
This study found that women who have pain after breast cancer treatment have higher levels of a substance called interleukin-6 in their bodies, which might be linked to their pain.
Methodology
A two-group comparison design was used to evaluate IL-6 and IL-6 receptors in women with breast cancer who reported painful symptoms of CIPN or no symptoms after chemotherapy.
Potential Biases
The cross-sectional design and single measurement time-point may introduce bias in the results.
Limitations
The study had a small sample size and included only an all white, non-Hispanic population, which may limit the generalizability of the findings.
Participant Demographics
Participants were Caucasian, non-Hispanic women diagnosed with grade II-III breast cancer.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website